杭州(zhou)尚健(jian)生物技術有(you)限(xian)公司是一家創新(xin)驅動型生物制藥企業,致力于惡性腫瘤等重大疾病的創新(xin)抗體(ti)藥物開發與(yu)商業化。
公(gong)司由呂明(ming)博(bo)士(shi)創(chuang)(chuang)(chuang)(chuang)建(jian)(jian),尚(shang)健生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)始終堅持技(ji)術(shu)創(chuang)(chuang)(chuang)(chuang)新引導產(chan)(chan)品創(chuang)(chuang)(chuang)(chuang)新。創(chuang)(chuang)(chuang)(chuang)建(jian)(jian)以(yi)來,尚(shang)健生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)組(zu)建(jian)(jian)了(le)一(yi)(yi)支擁有(you)豐富抗體藥物(wu)研(yan)發(fa)(fa)及產(chan)(chan)業(ye)化(hua)(hua)經驗的(de)(de)團隊,多(duo)名(ming)院士(shi)、國際(ji)和(he)國家專家擔綱科學(xue)顧問;以(yi)杭(hang)(hang)州(zhou)為總部和(he)產(chan)(chan)業(ye)化(hua)(hua)基地,同時(shi)在(zai)北京等(deng)地建(jian)(jian)立(li)了(le)國際(ji)領(ling)先(xian)的(de)(de)早(zao)期研(yan)發(fa)(fa)中心;與華東理工(gong)大學(xue)等(deng)知名(ming)科研(yan)院校開展(zhan)深度(du)合作;建(jian)(jian)立(li)了(le)國內領(ling)先(xian)的(de)(de)從抗體研(yan)發(fa)(fa)到規模化(hua)(hua)生(sheng)(sheng)(sheng)(sheng)(sheng)產(chan)(chan)和(he)臨床轉(zhuan)化(hua)(hua)的(de)(de)全流程技(ji)術(shu)體系,圍繞腫瘤領(ling)域布(bu)局了(le)一(yi)(yi)系列原創(chuang)(chuang)(chuang)(chuang)產(chan)(chan)品,申請(qing)國家及PCT專利100余項。2020年3月,在(zai)區(qu)政府的(de)(de)支持下(xia),尚(shang)健生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)將中國生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)技(ji)術(shu)股(gu)份(fen)有(you)限(xian)公(gong)司引入濱(bin)江(jiang),成立(li)合資公(gong)司——中生(sheng)(sheng)(sheng)(sheng)(sheng)尚(shang)健生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)醫藥(杭(hang)(hang)州(zhou))有(you)限(xian)公(gong)司,進一(yi)(yi)步加(jia)快創(chuang)(chuang)(chuang)(chuang)新抗體藥物(wu)產(chan)(chan)業(ye)化(hua)(hua),促(cu)進區(qu)域生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)醫藥產(chan)(chan)業(ye)迅速發(fa)(fa)展(zhan)。
在各級(ji)政府的大力支(zhi)持(chi)下,尚健生物(wu)啟動(dong)了抗(kang)(kang)體產業化基地建(jian)設項目,計劃(hua)通過2年(nian)時(shi)間,建(jian)設符合國(guo)際(ji)標準的抗(kang)(kang)體藥物(wu)規模(mo)化生產基地,推動(dong)多(duo)個(ge)創(chuang)新抗(kang)(kang)體產業化,努力成為(wei)國(guo)際(ji)領先(xian)、持(chi)續創(chuang)新的生物(wu)制藥企業,為(wei)全球患者(zhe)提(ti)供優質的中國(guo)抗(kang)(kang)體。